News

The jury decided that Wyeth failed to adequately warn the patient of the risks involved with the treatment. They also found that Wyeth acted with malice or reckless

Under the terms of the agreement, Debiopharm will fully manage and fund the development of Debio-0719, before out-licensing to sales and marketing partners in all territories outside of

Teva is the first company to file a copycat version of Focalin for approval and, as a result, has been awarded a 180-day period of marketing exclusivity. The

“Although we had data from previous toxicology studies, we decided to undertake additional studies in pigs and monkeys. The studies in monkeys were not required to proceed with

OctoPlus believes that Locteron has the potential to induce fewer side effects, improve patient compliance and provide a more convenient once every two weeks dosing schedule compared with

The compound, XL418 is an inhibitor of protein kinase B (PKB or AKT) and S6 Kinase (S6K), key components of the phosphoinosotide-3 kinase (PI3K) signaling pathway. Activation of

Lexicon's planned name change will be submitted for shareholder approval at its upcoming annual shareholder meeting. The company has the goal of advancing 10 drug candidates into human

In the phase IIa study, the primary endpoint was an expected improvement in AQLQ compared to placebo and the secondary endpoints incorporated measures of asthma control. “The profile

Platinum based therapy is the most widely used chemotherapy to treat ovarian cancer, but some women develop resistance to it. “There are very few drugs that will effectively